Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
Status:
Completed
Trial end date:
2021-02-10
Target enrollment:
Participant gender:
Summary
This randomized clinical trial was designed and intended to evaluate the efficacy of
Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome
(ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to find the best option for
the treatment and management of ARDS in COVID-19 patients.
Phase:
Phase 3
Details
Lead Sponsor:
M Abdur Rahim Medical College and Hospital
Collaborators:
Chattogram General Hospital Cox's Bazar 250 Bed District Sadar Hospital First affiliated Hospital of Xi'an Jiaoting University First Affiliated Hospital Xi'an Jiaotong University